Key Highlights

  • Gilead Sciences reported second-quarter Revenue of $7,803 million, up 10%, with Biktarvy alone contributing roughly $3.8 billion.
  • Oric Pharmaceuticals holds cash of $387.6 million, which management says funds operations into the second half of 2028.
  • Mineralys Therapeutics faces a single dated regulatory event, an FDA decision on lorundrostat targeted for December 22, 2026.
  • DiaMedica Therapeutics' Phase 2/3 stroke trial had surpassed 85% of its required 200 participants toward a prespecified interim analysis.

Biotechnology has always been the part of the Nasdaq Composite where the extremes live. On any given day the index carries a $180-billion-plus commercial giant alongside clinical-stage companies whose entire Market Value rests on a single molecule and a single data readout.

The five companies here span almost that full range. Gilead Sciences (NASDAQ:GILD) is a cash-generating large-cap. Mineralys Therapeutics (NASDAQ:MLYS) is weeks from a pivotal regulatory decision. Oric Pharmaceuticals (NASDAQ:ORIC) and Nkarta (NASDAQ:NKTX) are advancing oncology and cell-therapy programs into decisive trials. DiaMedica Therapeutics (NASDAQ:DMAC) is a micro-cap threading a narrow cash runway.

Together they map the risk spectrum investors actually navigate in this sector.

The September 2026 Backdrop: Catalyst Season Meets a Friendlier Rate Narrative

Two forces frame biotech as the fourth quarter approaches. The first is monetary. Clinical-stage developers burn cash for years before revenue, which makes them unusually sensitive to interest rates and to how cheaply the market will fund them. Commentators through 2026 have described a warmer tone toward the group as easing expectations firmed and generalist money crept back into risk assets. That does not lift every boat equally, and none of the specific fundamentals below depend on it.

The second force is the calendar. Autumn is dense with medical meetings and regulatory dates. The European Society for Medical Oncology congress in October, the American College of Rheumatology's Convergence in November, and a cluster of PDUFA decisions turn the season into a run of binary events. For catalyst-driven names, the next data slide often matters more than the macro.

The five companies here sit at different points on that map: one selling products at scale, one awaiting an approval decision, two reading out early trial data, and one funding the trials that will define it. The common thread is that biotech value still hinges on evidence and on the money to keep generating it.

Oric Pharmaceuticals (NASDAQ:ORIC): A Prostate-Cancer Phase 3 Anchors the Story

Oric Pharmaceuticals reported cash, cash equivalents and investments of $387.6 million as of June 30, 2026, which management said funds operations into the second half of 2028 and beyond the anticipated primary-endpoint readout of its lead Phase 3 trial. The company posted a second-quarter net loss of $41.5 million. Oric's lead program, rinzimetostat (previously ORIC-944), is a PRC2 inhibitor in the Phase 3 Himalayas-1 trial for metastatic castration-resistant prostate cancer. The company described a design of roughly 600 patients across more than 250 sites in 25 countries, randomizing rinzimetostat plus darolutamide against physician's choice, with radiographic progression-free survival as the primary endpoint. Its second program, enozertinib (previously ORIC-114), is an EGFR inhibitor in Phase 1b for EGFR-mutant non-small cell lung cancer, with data slated for the ESMO congress in October 2026. Oric has narrowed to two clinical bets and, by its own account, funded them past the pivotal prostate readout. The ESMO enozertinib data and further Himalayas-1 updates are the near-term swing factors; positive signals could reset sentiment, while any setback in either program would weigh heavily given the concentration. Treat trial outcomes as unknown until reported.

Gilead Sciences (NASDAQ:GILD): HIV Scale, an Oral PrEP Filing, and a Guidance Wrinkle

Gilead Sciences reported second-quarter 2026 total revenue of $7,803 million, up 10% year over year, with product sales of $7,627 million. HIV product sales rose 12% to $5,693 million, and Biktarvy contributed roughly $3.8 billion, up 7%. In oncology, Trodelvy sales grew 26% to $457 million, while cell-therapy sales fell 14% to $417 million and Yescarta declined 12% to $346 million. Gilead said the FDA accepted a supplemental New Drug Application for Yeztugo (lenacapavir) as a once-weekly oral 300-mg tablet for HIV pre-exposure prophylaxis; the injectable, twice-yearly Yeztugo was approved for PrEP in 2025. For full-year 2026 the company guided product sales of $30,100 million to $30,400 million and declared a third-quarter Dividend of $0.82 per share. Gilead's full-year non-GAAP diluted Earnings guidance was framed as a loss per share of $(0.65) to $(0.30), a figure that reflects charges rather than an operating collapse, since product sales continue to grow. Investors should read the GAAP and non-GAAP reconciliations for the drivers. HIV prevention, especially lenacapavir's oral extension, is the growth narrative to watch, offset by softness in older cell-therapy franchises. Guidance can change.

Mineralys Therapeutics (NASDAQ:MLYS): A December FDA Date Defines the Year

Mineralys Therapeutics is awaiting an FDA decision on lorundrostat, an aldosterone synthase inhibitor, for hypertension used in combination with other antihypertensive drugs. The company reported a PDUFA target action date of December 22, 2026. Its registrational package rests on the Phase 3 Launch-HTN and Phase 2 Advance-HTN trials, with the Transform-HTN open-label extension continuing to generate longer-term safety data. New Launch-HTN data in patients with chronic kidney disease were presented at a European hypertension meeting during 2026. Mineralys held cash, cash equivalents and investments of $661.4 million as of June 30, 2026, which it said funds planned operations, including a commercial launch of lorundrostat, into 2028. The company reported a second-quarter net loss of $241.1 million, up sharply from $43.3 million a year earlier, an increase it attributed primarily to a $200.0 million upfront payment to Tanabe. Dr. Terry Ferguson was named chief medical officer effective August 10, 2026. Mineralys is one of the cleaner catalyst setups on this list, a well-capitalized company approaching a single, dated regulatory verdict. The December PDUFA outcome is decisive; approval would shift the story to commercial execution in a large hypertension market, while a delay or complete response letter would be a major setback. Regulatory decisions are never guaranteed.

Nkarta (NASDAQ:NKTX): Off-the-Shelf Cell Therapy Turns to Autoimmune Disease

Nkarta is developing NKX019, an allogeneic, cryopreserved, off-the-shelf CD19-directed CAR-NK cell therapy engineered with membrane-bound IL-15. Its Ntrust-1 and Ntrust-2 trials are enrolling across six autoimmune indications: systemic sclerosis, idiopathic inflammatory myopathy, ANCA-associated vasculitis, rheumatoid arthritis, lupus nephritis and primary membranous nephropathy. Patients receive a three-dose cycle on Days 0, 3 and 7, and the company reported an FDA agreement permitting outpatient dosing in community settings. Nkarta said it will present initial NKX019 autoimmune clinical data at the American College of Rheumatology Convergence 2026 meeting, held November 6-11 in Orlando, with an oral presentation on idiopathic inflammatory myopathy on November 8, a systemic-sclerosis poster on November 9, and an overall-safety oral presentation on November 11. As of March 31, 2026 the company reported $266.7 million in cash, expected to fund operations into 2029, and a first-quarter net loss of $27.8 million, or $0.37 per share. Nkarta is testing whether off-the-shelf NK cells can deliver the immune "reset" that autologous CAR-T therapies have shown in autoimmune disease, without bespoke manufacturing. The November ACR data are the pivotal near-term catalyst; early efficacy and a clean safety profile would validate the approach, while thin or inconsistent results would raise questions. Early data are exploratory by nature.

DiaMedica Therapeutics (NASDAQ:DMAC): A Micro-Cap Balancing Stroke and Preeclampsia

DiaMedica Therapeutics is developing DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1, across two programs. In acute ischemic stroke, the Phase 2/3 ReMEDy2 trial had surpassed 85% of the 200 participants required to trigger a prespecified interim analysis, with roughly 70 activated sites; the company said it expects that interim analysis to read out in early 2027. In preeclampsia, interim Part 1a results from a South African Phase 2 study showed reductions in maternal blood pressure and uterine-artery pulsatility index, with Parts 1b and 2 expected to begin in September or October 2026. Health Canada cleared a separate Phase 2 dose-finding study in early-onset preeclampsia of roughly 30 patients, with first dosing expected in the fourth quarter of 2026. DiaMedica reported $5.1 million in cash and cash equivalents plus $38.4 million in marketable securities, totaling $43.5 million, as of June 30, 2026, and a second-quarter net loss of $10.1 million. Management said it expects funding to support planned studies and operations through 2027. DiaMedica is the highest-risk profile here, a micro-cap advancing two capital-intensive programs against a runway it describes as reaching through 2027. The ReMEDy2 interim in early 2027 is the defining event, with preeclampsia progress a secondary catalyst; a positive stroke signal could be transformative, but the tight cash position raises the odds of future financing. Nothing about the readout is assured.

What Investors Should Watch

The autumn calendar concentrates the risk. Oric's enozertinib data at ESMO in October and Nkarta's NKX019 presentations at ACR in early November are the clearest clinical catalysts. Mineralys carries the single dated regulatory event, its December 22 PDUFA decision on lorundrostat. Gilead's watch items are commercial and pipeline-driven: HIV prevention uptake and the once-weekly oral lenacapavir filing. DiaMedica's story runs on a longer fuse, with the ReMEDy2 stroke interim expected in early 2027.

Cash is the other lens. Gilead sells products at scale; Mineralys and Nkarta report multi-year runways; Oric says it is funded past its pivotal readout; DiaMedica's runway is the tightest and most likely to require attention. In clinical-stage biotech, the distance to the next data point and the money to reach it are inseparable.

A Cross-Section of Biotech Risk

Placed side by side, these five Nasdaq names are not a theme so much as a cross-section. Gilead shows what commercial scale looks like in HIV and oncology. Mineralys shows a de-risked-looking company still facing one hard regulatory gate. Oric and Nkarta show oncology and cell-therapy platforms approaching evidence that will make or unmake them. DiaMedica shows how thin the Margin for error runs at the small-cap end. For the biotech slice of the Nasdaq Composite, the lesson holds that value is created at catalysts and destroyed at them too. The macro backdrop may be friendlier than it was, but each of these stories still turns on its own data. Investors should size positions to that binary reality.